Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy
Open Access
- 8 October 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis: Integrative Cancer Research
- Vol. 32 (12), 1824-1831
- https://doi.org/10.1093/carcin/bgr222
Abstract
A considerable percentage of rectal cancers are resistant to standard preoperative chemoradiotherapy. Because patients with a priori-resistant tumors do not benefit from multimodal treatment, understanding and overcoming this resistance remains of utmost clinical importance. We recently reported overexpression of the Wnt transcription factor TCF4, also known as TCF7L2, in rectal cancers that were resistant to 5-fluorouracil-based chemoradiotherapy. Because Wnt signaling has not been associated with treatment response, we aimed to investigate whether TCF4 mediates chemoradioresistance. RNA interference-mediated silencing of TCF4 was employed in three colorectal cancer (CRC) cell lines, and sensitivity to (chemo-) radiotherapy was assessed using a standard colony formation assay. Silencing of TCF4 caused a significant sensitization of CRC cells to clinically relevant doses of X-rays. This effect was restricted to tumor cells with high T cell factor (TCF) reporter activity, presumably in a β-catenin-independent manner. Radiosensitization was the consequence of (i) a transcriptional deregulation of Wnt/TCF4 target genes, (ii) a silencing-induced G 2 /M phase arrest, (iii) an impaired ability to adequately halt cell cycle progression after radiation and (iv) a compromised DNA double strand break repair as assessed by γH2AX staining. Taken together, our results indicate a novel mechanism through which the Wnt transcription factor TCF4 mediates chemoradioresistance. Moreover, they suggest that TCF4 is a promising molecular target to sensitize resistant tumor cells to (chemo-) radiotherapy.Keywords
This publication has 47 references indexed in Scilit:
- A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancersNature, 2011
- A Re-evaluation of the “Oncogenic” Nature of Wnt/β-catenin Signaling in Melanoma and Other CancersCurrent Oncology Reports, 2010
- A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targetsInternational Journal of Cancer, 2010
- Colorectal cancerThe Lancet, 2010
- Wnt5a regulates distinct signalling pathways by binding to Frizzled2The EMBO Journal, 2009
- Nuclear cyclin D1: An oncogenic driver in human cancerJournal of Cellular Physiology, 2009
- γH2AX and cancerNature Reviews Cancer, 2008
- Diversity of LEF/TCF action in development and diseaseOncogene, 2006
- WNT and β-catenin signalling: diseases and therapiesNature Reviews Genetics, 2004
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001